Zymeworks upgraded by H.C. Wainwright with a new price target
$ZYME
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright upgraded Zymeworks from Neutral to Buy and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2025 | $33.00 | Equal Weight → Overweight | Wells Fargo |
| 12/3/2025 | $32.00 | Mkt Outperform | Citizens JMP |
| 10/24/2025 | $15.00 | Equal Weight | Wells Fargo |
| 10/14/2025 | $26.00 | Neutral → Buy | H.C. Wainwright |
| 10/10/2025 | $30.00 | Buy | B. Riley Securities |
| 5/20/2025 | Buy | TD Cowen | |
| 12/16/2024 | $18.00 | Neutral → Overweight | Analyst |
| 11/7/2024 | $10.00 → $25.00 | Market Perform → Outperform | Leerink Partners |
SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)
8-K - Zymeworks Inc. (0001937653) (Filer)
10-Q - Zymeworks Inc. (0001937653) (Filer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share. Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per co
VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum: Zymeworks' management will participate in one-on-one meetings and a fireside chat on May 20 at 9:00 am Eastern Time (ET) virtually.TD Cowen 7th Annual Oncology Innovation Summit: Zymeworks' management will participate in a fireside chat on May 27 at 4:30 pm ET virtually.2026 Jefferies Global Healthcare Confe
Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026China's NMPA has accepted the sBLA for zanidatamab; the U.S. FDA has granted Breakthrough Therapy Designation to zanidatamab in combination with fluoropyrimidine- and platinum-based chemotherapy (±) TEVIMBRA, for this indication.Presented new data from our Phase 1 trial of ZW191 at AACR, continuing to support best-in-class potential in ovarian and endometrial cancersPresented on emerging RAS inhibitor antibody-drug co
4 - Zymeworks Inc. (0001937653) (Issuer)
3 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00
Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00
Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00
• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati
VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr
Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET). About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
SC 13G - Zymeworks Inc. (0001937653) (Subject)